Evercore ISI Downgrades Inspire Medical Systems to 'Hold'
Evercore ISI Group has downgraded Inspire Medical Systems to a 'hold' rating with a $40 price target, a 7.94% downside from the current price.
Key Points
- Evercore ISI Group downgraded Inspire Medical Systems to a 'hold' rating with a $40 price target on June 23, 2026.
- Evercore ISI Group's $40 price target implies 7.94% downside from Inspire Medical Systems, Inc.'s ($INSP) current $43.45 share price.
- Inspire Medical Systems, trading at $43.20 on Friday, has a market cap of $1.25 billion and a P/E ratio of 9.88.
- Insider John Rondoni sold shares on multiple occasions in May 2026, while analyst consensus remains at 'hold' with a target mean price of $50.92.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Evercore ISI Group has made a significant move by downgrading Inspire Medical Systems, Inc. (NYSE:INSP) to a 'hold' rating, setting a new price target of $40. This change, announced on June 23, 2026, comes as part of the firm's reassessment of the company's prospects.
Evercore ISI Group vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Inspire Medical Systems, Inc. Stock Down 29.3%
Shares of NYSE:INSP traded at $43.20 on Friday. Inspire Medical Systems has a market capitalization of approximately $1.25 billion. The company's P/E ratio is 9.88, with a forward P/E of 33.60 and a beta of 0.73. Over the past 52 weeks, the stock has ranged from a low of $38.91 to a high of $147.03. Its 50-day moving average is $46.24, while the 200-day moving average stands at $72.32. The company also maintains a strong current ratio of 6.34 and a quick ratio of 4.35, with a debt-to-equity ratio of 3.73.
$INSP price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Inspire Medical Systems reported revenue of $915.25 million, with a modest growth rate of 1.6%. The company's net margin is 14.33%, and it achieved a return on equity of 18.37%. The next earnings report is expected on August 3, 2026.
Insider Buying and Selling at Inspire Medical Systems, Inc.
In May 2026, John Rondoni, the Chief Product and Innovation Officer, sold 2,641 shares on May 15 at an average price of $43.28, and an additional 700 shares on May 14 at $43.01. Meanwhile, insider transactions also included planned sales by Shawn McCormick and Georgia Melenikiotou, as well as purchases by Gary Lee Ellis and Cynthia Burks on April 30.
Analysts Set New Price Targets
On June 23, 2026, Evercore ISI Group downgraded Inspire Medical Systems to a 'hold' rating with a $40 price target. Other analysts, such as JP Morgan and Piper Sandler, recently maintained or downgraded the stock to similar ratings, with price targets ranging from $45 to $65. The consensus among 12 analysts is a 'hold' recommendation, with a target mean price of $50.92.
About Inspire Medical Systems
Inspire Medical Systems, Inc. is a healthcare company based in Golden Valley, Minnesota. It specializes in developing and selling minimally invasive medical devices for treating obstructive sleep apnea (OSA). The company's flagship product, the Inspire system, uses neurostimulation technology to help maintain an open airway during sleep. Founded in 2007, the company is led by CEO Timothy P. Herbert and employs around 1,333 people.
Bottom Line
The downgrade by Evercore ISI reflects a cautious stance on Inspire Medical Systems, as the new price target suggests limited upside from current levels. Investors often track these ratings for insights into market sentiment and potential stock movements. Remember, analyst ratings are opinions and should be considered alongside other factors in investment decisions.
Get Inspire Medical Systems, Inc. alerts
New 13F filings, insider trades, and analyst moves on $INSP, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.